Restating the opportunities investors have in making money from the health care sector is so redundant it boarders on insanity. With that said, it would be insane for you not to see the benefit investing in this sector will have on your portfolio. With these particular stocks, you’ll be guaranteed an investment in a company making solid returns over the past year and whose fundamentals are superb — hence the reason why they made this list.

I watch more than 5,000 publicly traded companies with my Portfolio Grader tool, ranking companies by a number of fundamental and quantitative measures.  Here they are, in alphabetical order. Each one of these stocks gets an “A” or “B” according to my research.

Abbott Laboratories (NYSE:ABT) discovers, develops, manufactures, and sells a diversified line of health care products. In the last year, ABT stock has gained almost 22%, compared to a nearly 6% gain for the Dow Jones. ABT stock gets an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of ABT stock.

Bristol-Myers Squibb (NYSE:BMY) sells its wide variety of health care products to wholesalers, retail pharmacies, hospitals and government entities and has posted at 24% gain over the past year. BMY stock gets a “B” for earnings momentum and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of BMY stock.

Eli Lilly (NYSE:LLY) discovers, develops, manufactures and sells its health care products in 125 countries. In the past 12 months, LLY stock is up 10%. LLY stock gets a “B” for its ability to exceed the consensus earnings estimates on Wall Street, an “A” for cash flow and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of LLY stock.

GlaxoSmithKline (NYSE:GSK) deals with vaccines, over-the-counter medicines and health-related consumer products and has watched its stock value increase nearly 14% in the past year. GSK stock gets an “A” for earnings momentum and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of GSK stock.

Johnson & Johnson (NYSE:JNJ) is one of the most recognizable names among global health care companies. JNJ stock is up 7% in the last 52 weeks. JNJ stock gets an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of JNJ stock.

Merck (NYSE:MRK) works with prescription medicines, vaccines, biologic therapies, animal health and consumer care products. Since last February, MRK stock has jumped almost 17%. MRK stock gets an “A” for earnings growth and a “B” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of MRK stock.

Pfizer (NYSE:PFE) develops health care products for the treatment of cardiovascular and metabolic diseases, central nervous system disorders, urogenital conditions, eye disease and endocrine disorders. PFE is up 10% in the last year. PFE stock gets an “A” for operating margin growth, an “A” for earnings growth, a “B” for cash flow and a “B” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of PFE stock.

Questcor Pharmaceuticals (NASDAQ:QCOR) is a biopharmaceutical company and the biggest winner on this list with a gain of 158% in one year. QCOR stock gets an “A” for sales growth, an “A” for earnings growth, an “A” for earnings momentum, an “A” for its ability to exceed the consensus earnings estimates on Wall Street, a “B” for the magnitude in which earnings projections have increased over the past month and an “A” for return on equity in my Portfolio Grader tool. For more information, view my complete analysis of QCOR stock.

Sanofi (NYSE:SNY) develops therapeutic solutions for various consumer needs, and is up 8% in the last year. SNY stock gets an “A” for sales growth, a “B” for earnings momentum and a “B” for cash flow in my Portfolio Grader tool. For more information, view my complete analysis of SNY stock.

Valeant Pharmaceuticals International (NYSE:VRX) is a specialty pharmaceutical company that rounds out the list with a gain of 25% in 12 months. VRX stock gets an “A” for sales growth, an “A” for earnings momentum, a “B” for its ability to exceed the consensus earnings estimates on Wall Street and a “B” for the magnitude in which earnings projections have increased over the past month in my Portfolio Grader tool. For more information, view my complete analysis of VRX stock.

Get more analysis of these picks and other publicly traded stocks with Louis Navellier’s Portfolio Grader tool, a 100% free stock rating tool that measures both quantitative buying pressure and eight fundamental factors.